Aldeyra Therapeu (ALDX) Stock Price, Quote & News

Company Profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator th...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 761 4904

Fax: 339 674 6495

Website: www.aldeyra.com

Address:

131 Hartwell Avenue, Suite 320, Lexington, United States

GoldmanSlaps Dec. 5 at 3:23 AM

$ALDX could this benefit us? https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

Fire_Truck Dec. 5 at 1:06 AM

$ALDX Ok im in. Grok says a 60-80% chance of approval this time. I guess im a gambler.

1 · Reply

CharlieeMungerTWITS Dec. 5 at 12:50 AM

$ALDX next target $6.30

0 · Reply

Iightning Dec. 5 at 12:10 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ALDX Contract: Dec 19 $5C Entry: 1.25 Exit: 1.99 Return: +59.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

MoneyGroupLLC Dec. 4 at 10:30 PM

Enter: $ALDX Calls Strike Price: $5 Expiry Date: JAN 16 2026 Buy in Price: $1.65 - $1.90 Sell Price: $3.30 Profit : +100% (Turn every $1 into $2.00) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ALDX_Bull Dec. 4 at 8:26 PM

$ALDX Almost there. Naysayers can say whatever they want. Reproxalap is for acute and the chamber trial very cleanly shows the acute activity. Better than steroids in pretty much every way. How do you measure acute in a field trial?? Even the most negative here will probably admit it is very safe. What is risk to FDA for approving it?

2 · Reply

RoyBasch Dec. 4 at 8:25 PM

$ALDX With ~ 5.57 million shares currently sold short (~ 10.3 % of float), short-sellers don’t have enough time left to cover without pushing the price sharply higher. If approval drops — expect a powerful squeeze

1 · Reply

RoyBasch Dec. 4 at 8:22 PM

$ALDX — Why Reproxalap Gets Approved Robust chamber efficacy backed by the FDA-requested study design, post-hoc analyses confirming a consistent treatment effect, no CMC concerns, and a clean safety profile across more than 2,900 patients. It’s exactly what the FDA asked for.

0 · Reply

Milanfinest Dec. 4 at 7:50 PM

$ALDX $ALDX so for the shorts : can u explain me as to a retard what is your verdict and price target?

1 · Reply

All4Retiring Dec. 4 at 6:36 PM

$ALDX INVA has a PDUFA 12/15 oral medication for drug resistant gonorhea with priority review. Please see year to date chart to compare to ALDX price action.

0 · Reply

Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript

Nov 13, 2025, 7:00 AM EST - 21 days ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 23 days ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Oct 28, 2025, 7:01 AM EDT - 5 weeks ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct 10, 2025, 4:32 AM EDT - 7 weeks ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALEC BDTX CHRS

Sep 3, 2025, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aug 19, 2025, 7:01 AM EDT - 3 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 6, 2025, 7:01 AM EDT - 4 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Jul 17, 2025, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jul 2, 2025, 9:23 PM EDT - 5 months ago

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Jun 26, 2025, 7:00 AM EDT - 5 months ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

May 29, 2025, 7:01 AM EDT - 6 months ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 7, 2025, 4:07 PM EDT - 7 months ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 7 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 4:42 PM EDT - 7 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter – Hagens Berman

May 6, 2025, 3:48 PM EDT - 7 months ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 5, 2025, 6:34 PM EDT - 7 months ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 7 months ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 7 months ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 7 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 7 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 7 months ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 7 months ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law

Apr 29, 2025, 9:49 AM EDT - 7 months ago

ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Apr 28, 2025, 9:00 PM EDT - 7 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

TTGT

Apr 28, 2025, 3:46 PM EDT - 7 months ago

ALDX NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of Pending Securities Investigation - Contact BFA Law if You Lost Money

Apr 27, 2025, 8:20 AM EDT - 7 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

Apr 25, 2025, 3:22 PM EDT - 7 months ago

ALDX SHAREHOLDER NEWS: Aldeyra Therapeutics, Inc. 75% Stock Plummet Leads to Securities Investigation - Investors are Urged to Contact BFA Law

Apr 25, 2025, 7:36 AM EDT - 7 months ago

ALDX SHAREHOLDERS: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) 75% Stock Drop Triggers Investigation – Contact BFA Law if You Lost Money

Apr 24, 2025, 3:18 PM EDT - 8 months ago

ALDX NOTICE: A Securities Investigation was initiated on behalf of Aldeyra Therapeutics, Inc. Investors - Contact BFA Law

Apr 23, 2025, 3:36 PM EDT - 8 months ago

ALDX INVESTIGATION: Aldeyra Therapeutics, Inc. is being Investigated for Securities Violations - Investors are Notified to Contact BFA Law

Apr 23, 2025, 8:18 AM EDT - 8 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

Apr 22, 2025, 3:23 PM EDT - 8 months ago

ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being Investigated - Contact the Firm if You Lost Money

Apr 21, 2025, 10:52 AM EDT - 8 months ago

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity

Apr 21, 2025, 8:33 AM EDT - 8 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

Apr 18, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation

Apr 17, 2025, 10:00 AM EDT - 8 months ago

Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

GoldmanSlaps Dec. 5 at 3:23 AM

$ALDX could this benefit us? https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

Fire_Truck Dec. 5 at 1:06 AM

$ALDX Ok im in. Grok says a 60-80% chance of approval this time. I guess im a gambler.

1 · Reply

CharlieeMungerTWITS Dec. 5 at 12:50 AM

$ALDX next target $6.30

0 · Reply

Iightning Dec. 5 at 12:10 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ALDX Contract: Dec 19 $5C Entry: 1.25 Exit: 1.99 Return: +59.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

MoneyGroupLLC Dec. 4 at 10:30 PM

0 · Reply

ALDX_Bull Dec. 4 at 8:26 PM

2 · Reply

RoyBasch Dec. 4 at 8:25 PM

1 · Reply

RoyBasch Dec. 4 at 8:22 PM

0 · Reply

Milanfinest Dec. 4 at 7:50 PM

$ALDX $ALDX so for the shorts : can u explain me as to a retard what is your verdict and price target?

1 · Reply

All4Retiring Dec. 4 at 6:36 PM

$ALDX INVA has a PDUFA 12/15 oral medication for drug resistant gonorhea with priority review. Please see year to date chart to compare to ALDX price action.

0 · Reply

TripleGateCptl Dec. 4 at 5:57 PM

$ALDX just FYI, when Todd said there hasn’t been turnover at FDA in ophthalmology…lol… It’s so funny. Technically those words are correct, but there is something he either doesn’t know, or is not saying. There was certain very important turnover that impacts ophthalmology greatly. And it hasn’t been in the news, so none of you geniuses know about it.

1 · Reply

NotHalfFast Dec. 4 at 5:02 PM

$ALDX just for the record, I’ve been here for a long time and have quietly watched all the fuckery and FUD, both current and in the past. Not gonna lie, Todd has a spotty track record with haughtiness but my read is we are good to go. ABBV ended the amateur hour attemp — Todd had the humility to change course and the wisdom to ask for help from the inventor of DED and will be rewarded for that. Still strong til the end

1 · Reply

steven1x Dec. 4 at 4:01 PM

$ALDX could not find todays webcast if so , but while waiting if new here or missed Here is Nov webcast … you can compare later https://wsw.com/webcast/jeff332/aldx/1839403?mobile=True

0 · Reply

All4Retiring Dec. 4 at 2:33 PM

$ALDX Piper Sandler Meeting This Morning with Todd I will post a link once it is available on the Aldeyra webite. Piper Sandler is NOT listed on Aldeyra's website as an analyst covering Aldeyra. Maybe we will see a initiate coverage note and price target shortly. I found it interesting how Todd talked about Abbvie's pre launch activities i.e. pricing, payer conversations, etc. Please listen once available.

2 · Reply

philipv777 Dec. 4 at 2:27 PM

$ALDX few observations from today’s unexpected Piper Sandler conference appearance: “If we knew something terrible, I wouldn’t be here.” “Everything feels on track.” “AbbVie has done everything you’d expect ahead of a launch.” Discussing AbbVie/ALDX payer and pricing work Dodging labeling discussions completely which he hadn’t done in the past. Last CRL was a total surprise and he said some of these things before April too, so take it with a grain of salt, but a good sign nevertheless.

1 · Reply

All4Retiring Dec. 4 at 1:56 PM

$ALDX

1 · Reply

All4Retiring Dec. 4 at 1:55 PM

$ALDX

0 · Reply

TripleGateCptl Dec. 4 at 12:15 PM

$ALDX are you here for more spanking? If you continued reading Todd’s email, past the part where he tells you that the Redness trials failed, you would notice that RENEW was thrown out by the FDA. So your buddies are knowingly presenting misleading information. I don’t think you have the knowledge to understand ALL of their fabrications, but you can read the comments to my CP…if you know how to look that up. The FDA asked for Study 031.

1 · Reply

All4Retiring Dec. 4 at 11:55 AM

$ALDX Is Todd at Piper Sandler this morning? Shows link to meeting in Stocktwits

0 · Reply

Iightning Dec. 4 at 7:50 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ALDX Contract: Dec 19 $5C Entry: 1.32 Exit: 2.51 Return: +89.15% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Nikata_G Dec. 4 at 2:59 AM

$ALDX lots of 2.5$ put Dec 19 contacts traded recently. Wonder if someone already knows something or simply hedging..

1 · Reply

HenryDotDotDot Dec. 3 at 10:21 PM

$ALDX The FDA has accepted the NDA package from ALDX in 2022. And since then the agency has only asked for at least one more well controlled symptom dry eye trial. The rest of the package has been accepted in 2022 without any more issues, and that's been the case for the last 3 years. So the fact that Norbert is criticizing ABBV and ALDX for using/presenting the data from the FDA accepted package is total nonsense. Again to Norbert, you don't get to claim what data isn't good enough, you are not the FDA.

2 · Reply

Market Cap	292.99M
Revenue (ttm)	0.00
Net Income (ttm)	-55.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	894,800
Avg Vol	709,774
Day's Range	N/A - N/A
Shares Out	60.16M
Stochastic %K	18%
Beta	0.83
Analysts	Strong Sell
Price Target	$9.00